XM does not provide services to residents of the United States of America.

China gloom overshadows Wall Street-led rebound



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>MORNING BID EUROPE-China gloom overshadows Wall Street-led rebound</title></head><body>

A look at the day ahead in European and global markets from Rae Wee


The rebound in global share markets proved short-lived in Asia on Tuesday, as yet another set of lacklustre economic indicators from China soured the mood and capped gains in Asian stocks.

That has set up a mixed opening in Europe, with EUROSTOXX 50 futures STXEc1 pointing to a positive start, while FTSE futures FFIc1 fell 0.3%.

Figures on British pay growth and joblessness are due later in the day just as London wakes up, where expectations are for them to point to a further easing of inflationary pressures.

That could pave the way for more rate cuts from the Bank of England, though doing so next week could surprise investors, given they are only pricing in a slim chance of 25 basis points worth of easing. 0#BOEWATCH

The Fed also meets next week and a 25bp cut is pretty much a done deal, so that leaves the fate of an outsized 50bp move in the hands of Wednesday's U.S. inflation report.

Turning the focus back to China, trade data on Tuesday showed exports unexpectedly picked up pace in August, but imports missed forecasts.

That followed Monday's figures on consumer prices, whose rise had little to do with a recovery in domestic demand as producer price deflation worsened.



Chinese stocks struggled to catch a bid on Tuesday and fell to a seven-month trough .CSI300. Meanwhile, underscoring the anaemic consumer demand, the CSI Tourism Index .CSI930633 sank to a record low.

It has been a downward trend for Chinese equities for months now, and it's obvious Beijing has to do a lot more to restore investor confidence in its ailing stock market.

Mounting trade tensions definitely are not helping as well.

The U.S. House of Representatives passed a bill this week that aims to restrict business with China's WuXi AppTec 603259.SS BGI and several other biotech companies on national security grounds, sending Hong Kong-listed shares of WuXi AppTec 2359.HK down more than 10% at one point.

Key developments that could influence markets on Tuesday:

- UK ILO unemployment rate (July)

- UK average weekly earnings 3M (July)

- Germany final CPI (August)


China consumer prices jump, producer deflation persists https://reut.rs/47lNrGr


Editing by Muralikumar Anantharaman

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.